Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Income towards Parent Company: 2015-2024

Historic Income towards Parent Company for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to $125.9 million.

  • Seres Therapeutics' Income towards Parent Company fell 115.63% to -$21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.2 million, marking a year-over-year decrease of 184.78%. This contributed to the annual value of $125.9 million for FY2024, which is 64.79% up from last year.
  • Per Seres Therapeutics' latest filing, its Income towards Parent Company stood at $125.9 million for FY2024, which was up 64.79% from $76.4 million recorded in FY2023.
  • Seres Therapeutics' Income towards Parent Company's 5-year high stood at $125.9 million during FY2024, with a 5-year trough of -$90.1 million in FY2020.
  • In the last 3 years, Seres Therapeutics' Income towards Parent Company had a median value of $76.4 million in 2023 and averaged $45.2 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first decreased by 26.30% in 2020, then spiked by 214.77% in 2023.
  • Over the past 5 years, Seres Therapeutics' Income towards Parent Company (Yearly) stood at -$90.1 million in 2020, then grew by 28.38% to -$64.5 million in 2021, then dropped by 3.17% to -$66.6 million in 2022, then soared by 214.77% to $76.4 million in 2023, then skyrocketed by 64.79% to $125.9 million in 2024.